Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance

Prostate

Volumn 71, Issue 16, 2011, Pages 1780-1789

  Avgeris, Margaritis ^a   Stravodimos, Konstantinos ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

cancer biomarker; kallikreins; KLK4; KLKs; prostate cancer; serine proteases

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 4; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOSTATISTICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80054075544     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21395     Document Type: Article

References (55)

1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13): 1310-1319.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
3. Yousef GM, Chang A, Scorilas A, Diamandis EP,. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276 (1): 125-133.
4. Borgono CA, Diamandis EP,. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4 (11): 876-890. (Pubitemid 39472954)
5. Sotiropoulou G, Pampalakis G, Diamandis EP,. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009; 284 (48): 32989-32994.
6. Mavridis K, Scorilas A,. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010; 6 (2): 269-285.
7. Avgeris M, Mavridis K, Scorilas A,. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391 (5): 505-511.
8. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53 (1): 68-80. (Pubitemid 350166735)
9. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA,. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin 2010; 60 (2): 70-98.
10. Schroder FH, Bangma CH, Roobol MJ,. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008; 53 (5): 901-908.
11. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ,. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009; 101 (11): 1833-1838.
12. Stephan C, Jung K, Lein M, Diamandis EP,. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007; 43 (13): 1918-1926. (Pubitemid 47287733)
13. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP,. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999; 59 (17): 4252-4256. (Pubitemid 29418738)
14. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K,. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999; 96 (6): 3114-3119. (Pubitemid 29148853)
15. Stephenson SA, Verity K, Ashworth LK, Clements JA,. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999; 274 (33): 23210-23214.
16. Hu JC, Zhang C, Sun X, Yang Y, Cao X, Ryu O, Simmer JP,. Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene 2000; 251 (1): 1-8. (Pubitemid 30339411)
17. Korkmaz KS, Korkmaz CG, Pretlow TG, Saatcioglu F,. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: Intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA Cell Biol 2001; 20 (7): 435-445. (Pubitemid 32881448)
18. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F,. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004; 64 (7): 2365-2370. (Pubitemid 38523888)
19. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP,. Human kallikrein 4: Quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 2005; 51 (8): 1432-1442. (Pubitemid 41060875)
20. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K,. Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001; 40 (50): 15341-15348. (Pubitemid 33151949)
21. Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS, Nelson PS,. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005; 62 (1): 1-13. (Pubitemid 39614288)
22. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP,. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001; 7 (8): 2380-2386. (Pubitemid 32751639)
23. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA,. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001; 7 (8): 2363-2371. (Pubitemid 32751637)
24. Papachristopoulou G, Avgeris M, Scorilas A,. Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost 2009; 101 (2): 381-387.
25. Escaff S, Fernandez JM, Gonzalez LO, Suarez A, Gonzalez-Reyes S, Gonzalez JM, Vizoso FJ,. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer 2010; 102 (5): 922-929.
26. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F,. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 2007; 67 (11): 5221-5230. (Pubitemid 46997260)
27. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA,. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005; 12 (3): 631-643. (Pubitemid 41482997)
28. Hekim C, Riipi T, Weisell J, Narvanen A, Koistinen R, Stenman UH, Koistinen H,. Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides. Biol Chem 2010; 391 (4): 475-479.
29. Nyberg P, Ylipalosaari M, Sorsa T, Salo T,. Trypsins and their role in carcinoma growth. Exp Cell Res 2006; 312 (8): 1219-1228.
30. Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR,. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate 2010; 70 (7): 788-796.
31. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schroder FH, Lilja H,. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010; 16 (12): 3232-3239.
32. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH,. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005; 63 (4): 324-329. (Pubitemid 40664343)
33. Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H,. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007; 53 (2): 233-240. (Pubitemid 46338267)
34. Bjartell A, Paju A, Zhang WM, Gadaleanu V, Hansson J, Landberg G, Stenman UH,. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 2005; 64 (1): 29-39. (Pubitemid 40734736)
35. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25 (4): 402-408. (Pubitemid 34164012)
36. Korbakis D, Gregorakis AK, Scorilas A,. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker. Clin Chem 2009; 55 (5): 904-913.
37. Mavridis K, Talieri M, Scorilas A,. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem 2010; 391 (4): 467-474.
38. Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A,. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Sci 2010; 101 (3): 693-699.
39. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, Samaratunga H, Gardiner RA, Clements JA,. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: Nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 2005; 12 (4): 875-889. (Pubitemid 41815782)
40. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, Diamandis EP,. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002; 48 (8): 1232-1240. (Pubitemid 34809831)
41. Linja MJ, Visakorpi T,. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004; 92 (4): 255-264. (Pubitemid 40128246)
42. Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA,. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol Cancer Res 2009; 7 (1): 129-141.
43. Yu H, Rohan T,. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92 (18): 1472-1489.
44. Massoner P, Ladurner-Rennau M, Eder IE, Klocker H,. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 2010; 103 (10): 1479-1484.
45. Zhang XQ, Lee MS, Zelivianski S, Lin MF,. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J Biol Chem 2001; 276 (4): 2544-2550.
46. Webber MM, Waghray A, Bello D,. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1 (10): 1089-1094.
47. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA,. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54 (9): 2372-2377. (Pubitemid 24138727)
48. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM,. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25 (4): 349-355. (Pubitemid 350002982)
49. Killian CS, Corral DA, Kawinski E, Constantine RI,. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192 (2): 940-947. (Pubitemid 23227414)
50. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG,. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75 (4): 1046-1053.
51. Cramer SD, Chen Z, Peehl DM,. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156 (2 Pt 1): 526-531. (Pubitemid 126445373)
52. Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T,. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008; 99 (2): 316-323. (Pubitemid 351228486)
53. Massoner P, Haag P, Seifarth C, Jurgeit A, Rogatsch H, Doppler W, Bartsch G, Klocker H,. Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: Local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction. Prostate 2008; 68 (11): 1165-1178.
54. Wang W, Mize GJ, Zhang X, Takayama TK,. Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int J Cancer 2010; 126 (3): 599-610.
55. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA,. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 2007; 67 (4): 348-360. (Pubitemid 46341076)